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1. Introduction 
Deep venous thrombosis of the lower limb is a common disease with an incidence of 80 per 
10000 (Patel et al 2011) and has potential fatal consequences in the form of pulmonary 
embolism.  
It is usually seen in patients undergoing major surgery particularly orthopaedic surgery, 
trauma, prolonged immobilisation or hypercoagulable states (such as in the context of 
malignancy). There are associations with drugs such as the oral contraceptive pill and 
hormone replacement therapy (tamoxifen) that predispose to hypercoagulability.  
2. Pathology and clinical presentation 
Deep venous thrombosis of the lower extremity can occur anywhere from the ankle to the 
IVC, however it is those that occur between the IVC and femoral veins that most often lead 
to venous hypertension, resulting in the more severe symptoms. They are also more likely to 
recur (Vendatham 2006).  
The clinical spectrum can range from being completely asymptomatic to post thrombotic 
syndrome: ulceration, pain, and intractable oedema.  
Traditionally, DVTs have been treated with the use of oral anticoagulation medication (such 
as warfarin) for a period of 6 months. However, this is associated with a high risk for 
recurrent thrombosis, and approximately one third will develop post thrombotic syndrome 
despite treatment (Prandoni et al 1996). The recurrence of DVT is thought to be related to 
damage to the venous valves during an episode of thrombosis and the low rate of 
recanalisation particularly in caval/iliac/femoral venous thrombosis, which leads to 
obstruction and venous hypertension. It has been suggested that anticoagulation therapy 
alone may be inadequate to prevent the damage to the venous valves in the setting of 
caval/iliac/femoral DVT. Moreover, it has been shown that early thrombus removal is 
associated with a lower incidence of symptoms related to post thrombotic syndrome 
(Sharafuddin 2003). These factors have prompted use of invasive techniques such as catheter 
directed thrombolysis and mechanical thrombectomy, particularly in the acute setting, for 
thrombus removal.  
There are currently two large randomised controlled trials (TORPEDO and ATTRACT) 
underway investigating the efficacy of these invasive techniques and early results suggest 
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that early intervention in the setting of acute DVT is associated with lower recurrence rates, 
lower incidence of post thrombotic syndrome and lower rates of fatal PE.  
Pending the results of these trials however, clinicians should assess the need for invasive 
measures on a case by case basis, based on the timing of the DVT, associated risk factors for 
development of DVT, risk factors for thrombolysis related bleeding, age and prognosis of 
the patient.  
3. Endovascular techniques 
The goals of endovascular treatment of acute DVT include: prevention of PE, early symptom 
relief, and prevention of post thrombotic syndrome (Vendatham 2006).  
The endovascular techniques available to achieve these goals include catheter directed 
thrombolysis, mechanical/rheolytic thrombectomy and stent placement. IVC filters can 
theoretically be used in conjunction with these techniques to reduce the rate of PE during 
therapy, although this is controversial.  
These techniques require knowledge of, and skills in, ultrasound guided needle punctures, 
wire and catheter manipulation, thrombolysis drug administration, placement of 
endovascular stents, and familiarity with the use of various mechanical/rheolytic 
thrombectomy devices. The specific equipment will vary according to their availability and 
preference.  
3.1 Catheter directed thrombolysis 
Thrombolytic agents activate plasminogen which leads to the breakdown of clot. Systemic 
thrombolysis results in better short and long term clinical results (Comerota & Aldridge 
1993; Gallus AS 1998; Schweizer J, et al 2000; Wells PS 2001) when compared with 
anticoagulation, but this is at the expense of an increase in serious bleeding and PEs.  
Catheter directed thrombolysis (CDT) has developed in response, in an effort to reduce the 
dose of systemic thrombolytic by delivering the agent at the site of thrombosis, allowing a 
relative higher concentration to reach the thrombus with a lower systemic dose. This also 
reduces the duration of the therapy and complication rates. In addition, this technique 
allows the simultaneous treatment of underlying lesions that are often the cause of the 
thrombosis itself.  
Indications for CDT should focus on patients who ideally are young and active and have a 
normal life expectancy. In older patients, CDT should be performed in cases of an acutely 
threatened limb. Both these groups should have acute symptomatic DVT or severe clot 
burden that involves the IVC. Threshold for thrombolysis in iliofemoral DVT should be 
lower than that for femoro-popliteal DVT, due to the higher risk of developing post 
thrombotic syndrome in the former group (discussed in previous sections). Patients who 
have propagation of clot despite anticoagulation should also be considered for treatment. 
CDT is most effective when instituted within 4 weeks of thrombosis.  
Contraindications are similar to thrombolysis of any site, and include recent major surgery, 
recent cerebrovascular bleed, recent CPR, pregnancy or coagulopathy. In cases of 
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phlegmasia cerulea dolens with contraindications to thrombolysis, surgical thrombectomy 
may be considered (Sharafuddin 2003).  
In order to effectively deliver the thrombolytic agent, the location and extent of the affected 
vessels must be elucidated, and this can be performed with ultrasound in the lower 
extremity. For the central venous system or the peripheral system, a venogram using CT, 
MRI or angiography can be used, which give a better appreciation of the extent and location 
of the clot.  
Once the inflow and outflow of the occluded segment is elucidated, the access site can 
be selected. Early experience with access sites centred on the internal jugular vein 
(Grosman & Macpherson 1999). However this has technical disadvantages such as the 
longer route of access causing catheter migration, catheters stimulating cardiac 
arrhythmias, and difficulty crossing venous valves. In the past, some authors also used 
the brachial vein and contralateral common femoral vein, which have also fallen out of 
favour. The ipsilateral popliteal access later became the route of choice for most 
authors, being easily punctured with ultrasound guidance, having less problems with 
venous valves, and providing direct access to the thrombosed segment (Grossman, 
1998; Sharafuddin 2003). Other common access routes include the common femoral vein 
(used in iliocaval disease) and posterior tibial vein (for infrapopliteal disease). 
Occasionally, antegrade and retrograde access is simultaneously used, with the 
catheters crossed, to treat both up and downstream disease (Molina et al 1992, Raju et al 
1998, Tarry et al 1994). In extensive and severe disease, particularly in the calf, selection 
of the smaller veins with the catheter is extremely difficult, and sometimes impossible, 
which leads to poor inflow and higher rates of rethrombosis. Comerota (1993) described 
infusion through the ipsilateral femoral artery to push the thrombolytic agent through 
the capillary bed and into the small veins of the calf, and potentially improving 
clearance of thrombosis in those very small veins.  
The equipment required in CDT includes: 
- Ultrasound machine and sterile probe cover 
- Local anaesthesia 
- Micropuncture set  
- 0.035in J-wire 
- Vascular sheath (usually 6 Fr or larger to accommodate infusion catheters, stents and 
mechanical thrombectomy devices) 
- 0.035in glidewire 
- Angiographic catheters (according to clinician’s preference such as Davis, Angled 
tapered, Bern) 
- Infusion catheters 
- Thombolytic agent  
- Heparin 
- IV Infusion sets 
Once access is achieved, usually via ultrasound guided micropuncture (Cook Inc, 
Bloomington, IN) of the popliteal vein, a vascular sheath is inserted (6Fr or larger to allow 
www.intechopen.com
 Deep Vein Thrombosis 
 
62
passage of an infusion catheter), and a diagnostic venogram performed either via the sheath 
or via a catheter. This may or may not be sufficient to visualise the extent of thrombosis. 
In either case, this is followed by a wire and angiographic catheter (usually 0.035in 
system, such as glidewire (Terumo, Somerset NJ) and a 5Fr angled tapered glidecatheter), 
which traverses the occluded segment. A venogram past the level of the occlusion is 
performed, usually in the IVC, to confirm intraluminal position, and absence of more 
centrally located clot.  
The thrombolytic agent is usually injected at this point, and a number of different 
thrombolytic strategies have been described. At our institution, we would lace the 
length of the thrombosed segment using 200,000IU of Urokinase as the diagnostic 
catheter is being retracted. An infusion catheter with an infusion length that covers the 
occluded segment is then selected, and is inserted over a wire. The active infusion 
segment of the catheter is placed over the thrombosed segment of vein, which allows 
direct delivery of thrombolytic agent throughout the length of the thrombus. An 
infusion of Urokinase would then be commenced, at a rate of between 100,000-150,000 
IU per hour. A Heparin infusion through the vascular sheath side arm is also 
commenced. The infusion is continued overnight, and patient nursed in a High 
Dependency Unit or Intensive Care Unit with one to one nursing. If the case arrives 
early in the morning, the infusion is left running until the mid afternoon. The patient 
will then return to the angiography suite for a venogram to reassess the degree of 
thrombosis and treat any underlying lesions.  
If significant thrombus remains after the initial infusion, the infusion can be continued if 
it is felt that the clot will continue to disintegrate. However, this increases the dose and 
the duration of therapy with the associated increased risks of thrombolysis. It also 
increases the length of hospital stay and potentially increases the costs of treatment. 
Currently, CDT combined with mechanical thrombectomy is the preferred treatment 
(Sharaffudin 2003).  
3.2 Mechanical thrombectomy 
Mechanical thrombectomy devices disturb and break up the thrombus and allow rapid 
clearance of a large clot burden without the risks of pharmacological thrombolysis. They can 
be used alone, in situations where rapid debulking of thrombus is crucial, without the need 
for pharmacological therapy. However, adjunctive use of mechanical thrombectomy with 
thrombolysis is the preferred option. They can be used before, after or both before and after 
thrombolytic therapy.  
The mechanism employed in the device can be divided into rotational devices and rheolytic 
devices. 
Rotational devices include the Amplatz Thrombectomy Device (Microvena, White Bear 
Lake, MN), and Trerotola Percutaneous Thrombectomy Device (Arrow International, 
Reading, PA). These employ a high-velocity rotating helix or nitinol cage to macerate 
thrombus. The Trellis device (Trellis-8; Bacchus Vascular, Santa Clara, California, USA) 
employs a sinusoidal nitinol wire to disintegrate thrombus and with thrombolytic agent 
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between proximal and distal balloons for control and to prevent PE. Rotational devices have 
direct contact with the endothelium and subsequently have the potential for endothelial 
damage. However there have been no studies to analyse their efficacy compared with 
rheolytic devices. 
Rheolytic devices include the Angiojet (Possis, Minneapolis,MN). The device uses high-
pressure saline jets to fragment the thrombus. The jets also create a negative pressure zone 
which draws the fragmented thrombus toward the catheter where it is aspirated and 
removed. A possible advantage of the Angiojet device is that there is no contact of the 
maceration component of the device with the vessel wall. However, its use of high-pressure 
saline jets carries a theoretical risk of haemolysis and the release of adenosine and 
potassium. (Zhu, 2008) This has been linked to the incidence of bradyarrhythmia in cardiac 
applications of the device (Lee et al, 2005) or haemoglobinuria. 
Ultrasound enhanced devices include the EKOS Endowave (EKOS Corporation, Bothell, 
WA, USA) and Omniwave (Omnisonics Medical Technologies, Wilmington, MA, USA). 
These are catheters that contain multiple ultrasound transducers, which radially emit 
high-frequency, low-energy ultrasound energy. The ultrasonic energy expands and thins 
the fibrin component of thrombus, exposing plasminogen receptor sites, and the 
ultrasound forces thrombolytic into the clot and keeps it there (Francis et al, 1995). This 
technique may be associated with fewer haemolytic effects than rheolytic thrombectomy 
(Lang et al, 2008) and has a lower potential for endothelial damage than rotational 
thrombectomy devices.  
We prefer the use of the Angiojet system at our institution, as an adjunctive modality to 
CDT. The timing of its use is dependent on the case, and preference of the interventionist. 
However, the method is the same in either situation. The Angiojet catheters come in a range 
of sizes and lengths, we prefer the 5 and 6Fr systems. The device is passed several times 
across the thrombosed segment over a wire and under fluoroscopic visualisation. In order to 
minimise the risk of haemolysis, each pass is limited to 30 seconds with 10 second rests in 
between.  
The potential added benefit of the Angiojet system is the ability of the catheters to ‘pulse 
spray’ thrombolytic agent using high pressure jets into the thrombus itself, improving 
delivery.  
4. Results 
4.1 Catheter directed thrombolysis 
To date, the largest DVT thrombolytic database is the venous registry (Mewissen 1999), 
which is a prospective registry of patients with a DVT who underwent CDT with urokinase. 
473 patients were enrolled with 287 patients followed up at 1 year. 83% of patients had 
thrombolysis >50%. There were also a strong relationship between early thrombus removal 
and 1- year patency (primary patency rate of 60%). Major bleeding complications occurred 
in 11%, most often at the puncture site. 1% of patients developed a PE. Two patients (<1%) 
died (one from PE and one from intracranial haemorrhage).  
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Grunwald and Hofmann (2004) retrospectively analysed 74 patients who underwent CDT 
for DVT and compared Urokinase, Alteplase and Reteplase. They found that there was no 
statistical difference between infusion times, success rates and complication rates between 
the three agents. However, they did find that the new recombinant agents are significantly 
less expensive than Urokinase in the United States.  
No RCTs have been published looking at CDT in acute DVT. However, currently the 
TORPEDO trial is underway which is a large scale RCT looking at the efficacy of CDT vs 
anticoagulation in treatment of DVT. Mid term results show that CDT is superior to 
anticoagulation therapy alone in the prevention of recurrence of DVT, reduction in PTS, and 
reduction of hospital stays.  
Similarly the ATTRACT Trial is currently underway looking at the efficacy of CDT.  
4.2 Mechanical thrombectomy 
No large randomised control studies have been published looking at mechanical 
thrombectomy in DVT.  
An analysis by Karthikesalingam et al (2011) on 16 retrospective case series on the use of 
mechanical thrombectomy in DVT, with a total of 481 patients, looked at its efficacy. They 
found successful thrombolysis (>50% lysis) in 83-100% of patients. Bleeding complications 
requiring transfusion were seen in 7.5%. Symptomatic PE was seen in <1%. No procedure 
related deaths or strokes were seen. Of the studies that did look at mid term follow up, 75-
98% of patients demonstrated significant improvement of symptoms and similar 
improvement in radiological findings.  
5. Adjunctive procedures 
DVT, particularly in the iliocaval system, can be associated with chronic venous obstruction, 
which can lead to valvular insufficiency and consequently venous hypertension. This in turn 
is associated with a higher incidence of post thrombotic syndrome (PTS). There are multiple 
other causes of venous obstruction, which include May Thurner syndrome, external 
compression (e.g. cancer, lymphocoeles) and retroperitoneal fibrosis. Very frequently, 
thrombolysis and thrombectomy can uncover the underlying lesion which precipitated the 
venous thrombosis. Failure to identify and treat these lesions, despite successful 
thrombolysis, can result in higher rates of recurrence, and the development of PTS.  
The advantage of CDT as compared with anticoagulation therapy alone in the treatment of 
acute DVT, is that it allows the opportunity to treat the underlying lesion and restore flow in 
most cases. Obviously, non mechanical underlying issues must also be addressed, such as 
underlying prothrombotic syndromes.  
The objective is to restore flow and the measures employed usually involve angioplasty 
and stenting of the lesion. Angioplasty and stenting in the setting of obstruction has been 
shown to improve quality of life and improve symptoms (Hartung et al 2005, Neglen P et 
al 2005, Raju S et al 2002;). The lesions treated usually lie within the IVC, iliac and 
femoral veins. It has not been shown that angioplasty and stenting of lesions below this 
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level is of any benefit. However, chronic lesions do benefit as well as acute obstructions 
(Titus 2011).  
The procedure is similar to angioplasty of the arterial system. Once access is achieved, 
heparin is given if anticoagulation has not been already instituted. A wire is passed across 
the lesion, followed by a catheter. Any wire can be used however 0.035in wires are 
preferred. This is usually not too difficult in an acute thrombus, which is soft, and has not 
had time to organise. Contrast is injected beyond the lesion to ensure intraluminal 
position. The catheter is then exchanged for a balloon which is usually sized 
approximately 20% greater than the expected calibre of the vein. Angioplasty of the 
venous system is different from the arterial system, in that the balloons can be oversized 
to a greater extent than in the arteries. There is also a greater propensity for veins to have 
elastic recoil, such that even with aggressive angioplasty using high pressure balloons, the 
veins collapse back to their obstructed state. In other cases there is persistent stenosis in 
the vein post angioplasty. When this is the case, stenting is performed. These are also 
oversized in relation to the vein.  
6. Use of IVC filters 
The use of CDT and mechanical thrombectomy devices carry the theoretical increased risk 
of pulmonary embolisation. This has not been proven in any large scale study, and it is 
unclear based on current data whether this is true. In a review study by Grossman 1998, 2 
out of 263 (0.7%) patients developed a PE post CDT. This is compared to the incidence of PE 
in patients treated with heparin alone for DVT ranging from 0-56% for symptomatic emboli, 
and 0-8% for asymptomatic emboli (Leizorovicz et al 1994, Sirgusa et al 1996, Levine et al 
1995, Piccioli et al 1996).  
In addition, no large studies are available that looks at whether IVC filters reduce the 
incidence of PE following CDT or mechanical thrombectomy. Given the lack of data on their 
use, prophylactic IVC filters prior to commencement of CDT and/or mechanical 
thrombectomy has been debated.  
In a systematic review (Karthikesalingam et al 2011) of mechanical thrombectomy between 
1999 and 2009, the use of prophylactic IVC filters was variable between the various authors. 
Almost all authors report 0% PE on follow up CTPA whether IVC filters were inserted or not. 
One author (Arko et al 2007) reports a 17% PE rate, all asymptomatic, in patients where no IVC 
filter was placed. In those that had a filter, Arko found no PE. All deaths were unrelated to the 
thrombectomy (either myocardial infarct or cancer) and no patients died of PE.  
The role IVC filters therefore is not known and there are no current recommendations 
regarding their use. However they are not without risk, albeit small. Filter migration, filter 
fracture, break through PE have all been described, as well as complications associated with 
their retrieval.  
Placement of IVC filters remain at the discretion of the interventionist. In the presence of 
free-floating IVC thrombus or in patients with limited cardiopulmonary reserve who are 
unlikely to tolerate minor embolic events, IVC filtration may be appropriate with use of 
permanent (Tarry WC Ann Vasc Surg 1994) or temporary filters (Lorch et al 2000). 
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Fig. 1. 20 y.o. girl with acute DVT and swollen, dusky leg. Popliteal access has been achieved 
and venogram demonstrates thrombus in the femoral vein.  
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Fig. 2. Same patient. Thrombus extends into common femoral vein.  
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Fig. 3. Same patient. Thrombus extending into iliac veins.  
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Fig. 4. Same patient. IVC filter placed prior to commencement of procedure. Infusion 
catheter placed through the thrombus and Urokinase infusion commenced.  
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Fig. 5. Post 18 hours CDT. Thrombus still present in femoral vein.  
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Fig. 6. Post 18 hours CDT. Persistent thrombus in iliac veins.  
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Fig. 7. Post mechanical thrombectomy with Angiojet system demonstrates clearance of 
thrombus.  
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Fig. 8. Improvement of thrombus in iliac veins post Angiojet.  
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Fig. 9. Angioplasty of the common iliac vein 
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Fig. 10. Stent deployed in the left iliac vein with good flow through the vessel.  
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Endovascular techniques are important therapeutic options in the prevention of limb loss, 
recurrence and post thrombotic syndrome related to acute DVT, and have been shown to be 
superior to anticoagulation therapy alone. It also is advantageous in uncovering and 
treating underlying lesions that contribute to the DVT.  
No guidelines are available currently in terms of patient selection, techniques and the use of 
IVC filters and at present these decisions are made on a case by case basis at the discretion of 
the interventionist. Large randomized controlled trials underway currently will hopefully 
be able to shed more insight on these issues.  
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